ViroPharma (VPHM)

Add to Watchlists Create an Alert
26.64 +0.54  +2.07%   NASDAQ May 23, 2:51PM BATS Real time Currency in USD

ViroPharma R&D Expense Quarterly:

17.20M for March 31, 2013
View Full Chart

ViroPharma R&D Expense Quarterly Chart

    ViroPharma Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 17.20M
    Dec. 31, 2012 19.14M
    Sept. 30, 2012 16.55M
    June 30, 2012 16.62M
    March 31, 2012 15.40M
    Dec. 31, 2011 12.71M
    Sept. 30, 2011 22.93M
    June 30, 2011 20.42M
    March 31, 2011 10.43M
    Dec. 31, 2010 10.46M
    Sept. 30, 2010 10.19M
    June 30, 2010 9.224M
    March 31, 2010 9.741M
    Dec. 31, 2009 8.925M
    Sept. 30, 2009 11.01M
    June 30, 2009 12.47M
    March 31, 2009 19.80M
    Dec. 31, 2008 19.35M
    Sept. 30, 2008 15.07M
    June 30, 2008 15.04M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    VPHM R&D Expense Quarterly Benchmarks

    Companies
    Halozyme Therapeutics 18.57M
    Incyte 52.76M
    Optimer Pharmaceuticals 11.87M

    VPHM R&D Expense Quarterly Rankings

    Overall 94th percentile
    415 of 8006
    Sector 84th percentile
    104 of 686 in Healthcare
    Industry 84th percentile
    38 of 248 in Biotechnology

    VPHM R&D Expense Quarterly Range, Past 5 Years

    Minimum 8.925M Dec 2009
    Maximum 22.93M Sep 2011
    Average 14.63M